Diagnostic Bioliquid Markers for Pancreatic Cancer: What We Have vs. What We Need
Pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, currently has a dismal five-year survival rate of approximately 10% due to late diagnosis and a lack of efficient treatment options such as surgery. Furthermore, the majority of PDAC patients have surgically unresect...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-04-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/9/2446 |
| _version_ | 1797602925778829312 |
|---|---|
| author | Geou-Yarh Liou Crystal J. Byrd |
| author_facet | Geou-Yarh Liou Crystal J. Byrd |
| author_sort | Geou-Yarh Liou |
| collection | DOAJ |
| description | Pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, currently has a dismal five-year survival rate of approximately 10% due to late diagnosis and a lack of efficient treatment options such as surgery. Furthermore, the majority of PDAC patients have surgically unresectable cancer, meaning cancer cells have either reached the surrounding blood vessels or metastasized to other organs distant from the pancreas area, resulting in low survival rates as compared to other types of cancers. In contrast, the five-year survival rate of surgically resectable PDAC patients is currently 44%. The late diagnosis of PDAC is a result of little or no symptoms in its early stage of development and a lack of specific biomarkers that may be utilized in routine examinations in the clinic. Although healthcare professionals understand the importance of early detection of PDAC, the research on the subject has lagged and no significant changes in the death toll of PDAC patients has been observed. This review is focused on understanding potential biomarkers that may increase the early diagnosis of PDAC patients at its surgically resectable stage. Here, we summarize the currently available biomarkers used in the clinic as well as those being developed with the hope of providing insight into the future of liquid biomarkers to be used in routine examinations for the early diagnosis of PDAC. |
| first_indexed | 2024-03-11T04:23:25Z |
| format | Article |
| id | doaj.art-9aa8a832645241baa471866063d20e9a |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T04:23:25Z |
| publishDate | 2023-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-9aa8a832645241baa471866063d20e9a2023-11-17T22:39:51ZengMDPI AGCancers2072-66942023-04-01159244610.3390/cancers15092446Diagnostic Bioliquid Markers for Pancreatic Cancer: What We Have vs. What We NeedGeou-Yarh Liou0Crystal J. Byrd1Center for Cancer Research and Therapeutic Development, Clark Atlanta University, Atlanta, GA 30314, USADepartment of Biological Sciences, Clark Atlanta University, Atlanta, GA 30314, USAPancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, currently has a dismal five-year survival rate of approximately 10% due to late diagnosis and a lack of efficient treatment options such as surgery. Furthermore, the majority of PDAC patients have surgically unresectable cancer, meaning cancer cells have either reached the surrounding blood vessels or metastasized to other organs distant from the pancreas area, resulting in low survival rates as compared to other types of cancers. In contrast, the five-year survival rate of surgically resectable PDAC patients is currently 44%. The late diagnosis of PDAC is a result of little or no symptoms in its early stage of development and a lack of specific biomarkers that may be utilized in routine examinations in the clinic. Although healthcare professionals understand the importance of early detection of PDAC, the research on the subject has lagged and no significant changes in the death toll of PDAC patients has been observed. This review is focused on understanding potential biomarkers that may increase the early diagnosis of PDAC patients at its surgically resectable stage. Here, we summarize the currently available biomarkers used in the clinic as well as those being developed with the hope of providing insight into the future of liquid biomarkers to be used in routine examinations for the early diagnosis of PDAC.https://www.mdpi.com/2072-6694/15/9/2446pancreatic ductal adenocarcinomabiomarkerearly detectionearly diagnosisresectable pancreatic cancersecreted factors |
| spellingShingle | Geou-Yarh Liou Crystal J. Byrd Diagnostic Bioliquid Markers for Pancreatic Cancer: What We Have vs. What We Need Cancers pancreatic ductal adenocarcinoma biomarker early detection early diagnosis resectable pancreatic cancer secreted factors |
| title | Diagnostic Bioliquid Markers for Pancreatic Cancer: What We Have vs. What We Need |
| title_full | Diagnostic Bioliquid Markers for Pancreatic Cancer: What We Have vs. What We Need |
| title_fullStr | Diagnostic Bioliquid Markers for Pancreatic Cancer: What We Have vs. What We Need |
| title_full_unstemmed | Diagnostic Bioliquid Markers for Pancreatic Cancer: What We Have vs. What We Need |
| title_short | Diagnostic Bioliquid Markers for Pancreatic Cancer: What We Have vs. What We Need |
| title_sort | diagnostic bioliquid markers for pancreatic cancer what we have vs what we need |
| topic | pancreatic ductal adenocarcinoma biomarker early detection early diagnosis resectable pancreatic cancer secreted factors |
| url | https://www.mdpi.com/2072-6694/15/9/2446 |
| work_keys_str_mv | AT geouyarhliou diagnosticbioliquidmarkersforpancreaticcancerwhatwehavevswhatweneed AT crystaljbyrd diagnosticbioliquidmarkersforpancreaticcancerwhatwehavevswhatweneed |